POTENTIAL HERB-DRUG INTERACTION OF DECALEPIS HAMILTONII VIA P-GP MEDIATED PHARMACOKINETIC INTERACTION WITH FEXOFENADINE IN RATS: AN IN SITU AND IN VIVO STUDY

DHANUNJAYA SANDOPA; CHITRA VELLAPANDIAN

doi:10.22159/ijap.2023v15i5.48677

Authors

DHANUNJAYA SANDOPA Department of Pharmacology, Sri Padmavathi School of Pharmacy, Tiruchanur, Tirupathi-517503, India https://orcid.org/0000-0002-1041-7980
CHITRA VELLAPANDIAN Department of Pharmacology, SRM College of Pharmacy, SRMIST, Kattankulathur-603203, Tamil Nadu, India

DOI:

https://doi.org/10.22159/ijap.2023v15i5.48677

Keywords:

Decalepis hamiltonii, Fexofenadine, P-glycoprotein, Intestinal permeability, Pharmacokinetics

Abstract

Objective: The objective of this study was to investigate the influence of Decalepis hamiltonii (D. hamiltonii), a traditional plant used in herbal medicine, on the intestinal absorption and pharmacokinetics of fexofenadine, a substrate of P-glycoprotein (P-gp), in rats.

Methods: In situ intestinal perfusion tests were conducted to assess the intestinal permeability of fexofenadine. P-gp ATPase activity was also evaluated to understand the modulatory effects of D. hamiltonii on P-gp. An in vivo pharmacokinetic investigation was performed by administering oral fexofenadine to rats.

Results: The in situ study results revealed that the effective permeation (Peff) of fexofenadine was significantly diminished (p<0.001***) in aqueous extract of D. hamiltonii (AREDH, 200 mg/kg p. o.) pretreated group compared to normal control indicating modulation in absorption. Further, there was significant augmentation (p<0.01**) of P-gp ATPase activity in AREDH pretreated group (200 mg/kg p. o.) compared normal control indicating P-gp inductive potential of D. hamiltonii. Pharmacokinetic study results revealed that the peak plasma concentration (Cmax) and the area under the concentration-time curve (AUC) of fexofenadine was significantly downregulated (p<0.001***) in AREDH pretreated group (200 mg/kg p. o.) compared to the normal control group indicating the compromised absorption and bioavailability. However, no significant changes were observed in fexofenadine half-life (T1/2 k10), time to reach peak plasma concentration (Tmax), or elimination rate constant (k10).

Conclusion: In conclusion, D. hamiltonii significantly reduced the oral bioavailability of fexofenadine by promoting P-gp-mediated drug efflux during intestinal absorption. This suggests that the modulatory characteristics of D. hamiltonii may lead to herb-drug interactions when taken in combination with xenobiotics, emphasizing the importance of considering such interactions in clinical practice and further research.

Downloads

Download data is not yet available.

References

Srivastava A, Shivanandappa T. Hepatoprotective effect of the aqueous extract of the roots of decalepis hamiltonii against ethanol-induced oxidative stress in rats. Hepatol Res. 2006 Aug;35(4):267-75. doi: 10.1016/j.hepres.2006.04.011. PMID 16777477.

Murthy KN, Rajasekaran T, Giridhar P, Ravishankar GA. Antioxidant property of decalepis hamiltonii wight and Arn. Indian J Exp Biol. 2006 Oct;44(10):832-7. PMID 17131914.

Ragini V. Fractionation and evaluation of antidiabetic, antihyperlipidemic, and antioxidant activity of decalepis hamiltonii and shorea tumbuggaia. Asian J Pharm Clin Res. 2014 Sep;7(4):50-7.

Thangadurai D, Anitha S, Pullaiah T, Reddy PN, Ramachandraiah OS. Essential oil constituents and in vitro antimicrobial activity of decalepis hamiltonii roots against foodborne pathogens. J Agric Food Chem. 2002 May 22;50(11):3147-9. doi: 10.1021/jf011541q, PMID 12009977.

Giridhar P, Rajasekaran T, Ravishankar GA. Improvement of growth and root-specific flavour compound 2-hydroxy-4-methoxy benzaldehyde of micropropagated plants of decalepis hamiltonii wight and Arn., Under triacontanol treatment. Sci Hortic. 2005 Sep 1;106(2):228-36. doi: 10.1016/j.scienta.2005.02.024.

Srikanta BM, Nayaka MA, Dharmesh SM. Inhibition of helicobacter pylori growth and its cytotoxicity by 2-hydroxy 4-methoxy benzaldehyde of decalepis hamiltonii (Wight and Arn); a new functional attribute. Biochimie. 2011 Apr;93(4):678-88. doi: 10.1016/j.biochi.2010.12.009. PMID 21185348.

Sowbhagya RG, Lakshminarayana R, Raghuveer BS, Ravikiran T. Studies on ellagic acid and 4-hydroxyisophthalic acid isolated from swallow root (Decalepis hamiltonii). Int J Pharm Pharm Sci. 2016 Jun;8(6):278-85.

Mertens Talcott SU, De Castro WV, Manthey JA, Derendorf H, Butterweck V. Polymethoxylated flavones and other phenolic derivates from citrus in their inhibitory effects on P-glycoprotein-mediated transport of talinolol in Caco-2 cells. J Agric Food Chem. 2007 Apr 4;55(7):2563-8. doi: 10.1021/jf063138v, PMID 17348674.

Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol. 1999;39:361-98. doi: 10.1146/annurev.pharmtox.39.1.361. PMID 10331089.

Goda K, Bacso Z, Szabo G. Multidrug resistance through the spectacle of P-glycoprotein. Curr Cancer Drug Targets. 2009 May;9(3):281-97. doi: 10.2174/156800909788166493, PMID 19442049.

Matheny CJ, Lamb MW, Brouwer KR, Pollack GM. Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation. Pharmacotherapy. 2001 Jul;21(7):778-96. doi: 10.1592/phco.21.9.778.34558, PMID 11444575.

Kurniawan SV, Sugiarti L, Wanandi SI, Louisa M. Piperine in the prevention of the decreased tamoxifen sensitivity in mcf-7 breast cancer cell line. Int J App Pharm. 2018 Dec 20;10(1):335-7. doi: 10.22159/ijap.2018.v10s1.74.

Simpson K, Jarvis B. Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. Drugs. 2000 Feb;59(2):301-21. doi: 10.2165/00003495-200059020-00020, PMID 10730552.

Jin MJ, Han HK. Effect of piperine, a major component of black pepper, on the intestinal absorption of fexofenadine and its implication on food-drug interaction. J Food Sci. 2010 Apr;75(3):H93-6. doi: 10.1111/j.1750-3841.2010.01542.x. PMID 20492299.

Teng YN, Wang CCN, Liao WC, Lan YH, Hung CC. Caffeic acid attenuates multi-drug resistance in cancer cells by inhibiting efflux function of human P-glycoprotein. Molecules. 2020 Jan 7;25(2):247. doi: 10.3390/molecules25020247, PMID 31936160.

Wang S, Tan N, Ma C, Wang J, Jia P, Liu J. Inhibitory effects of benzaldehyde, vanillin, muscone and borneol on P-glycoprotein in caco-2 cells and everted gut sac. Pharmacology. 2018;101(5-6):269-77. doi: 10.1159/000487144, PMID 29502118.

Muthusamy G, Gunaseelan S, Prasad NR. Ferulic acid reverses P-glycoprotein-mediated multidrug resistance via inhibition of PI3K/Akt/NF-κB signaling pathway. J Nutr Biochem. 2019 Jan;63:62-71. doi: 10.1016/j.jnutbio.2018.09.022. PMID 30342318.

Sandopa D, Vellapandian C. Herbal drug interaction possibility with HPTLC standardized aqueous root extract of decalepis hamiltonii: an in silico approach. J Pharm Neg Results. 2022;13(4):1806-13. doi: 10.47750/pnr.2022.13.04.248.

Muthusamy G, Balupillai A, Ramasamy K, Shanmugam M, Gunaseelan S, Mary B. Ferulic acid reverses ABCB1-mediated paclitaxel resistance in MDR cell lines. Eur J Pharmacol. 2016 Sep 5;786:194-203. doi: 10.1016/j.ejphar.2016.05.023. PMID 27262378.

Salphati L, Childers K, Pan L, Tsutsui K, Takahashi L. Evaluation of a single-pass intestinal-perfusion method in rat for the prediction of absorption in man. J Pharm Pharmacol. 2001 Jul;53(7):1007-13. doi: 10.1211/0022357011776252, PMID 11480535.

Varma MV, Panchagnula R. Prediction of in vivo intestinal absorption enhancement on P-glycoprotein inhibition, from rat in situ permeability. J Pharm Sci. 2005 Aug;94(8):1694-704. doi: 10.1002/jps.20309, PMID 15986467.

Neerati P, Ganji D, Bedada SK. Study on in situ and in vivo absorption kinetics of phenytoin by modulating P-glycoprotein with verapamil in rats. Eur J Pharm Sci. 2011 Sep 18;44(1-2):27-31. doi: 10.1016/j.ejps.2011.05.005. PMID 21640186.

Neerati P, Bedada SK. Effect of diosmin on the intestinal absorption and pharmacokinetics of fexofenadine in rats. Pharmacol Rep. 2015 Apr;67(2):339-44. doi: 10.1016/j.pharep.2014.09.010. PMID 25712660.

Takara K, Ohnishi N, Horibe S, Yokoyama T. Expression profiles of drug-metabolizing enzyme CYP3A and drug efflux transporter multidrug resistance 1 subfamily mRNAS in small intestine. Drug Metab Dispos. 2003 Oct;31(10):1235-9. doi: 10.1124/dmd.31.10.1235, PMID 12975332.

Yamazaki M, Neway WE, Ohe T, Chen I, Rowe JF, Hochman JH. In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results. J Pharmacol Exp Ther. 2001 Mar;296(3):723-35. PMID 11181899.

Chiou WL, Barve A. Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats. Pharm Res. 1998 Nov;15(11):1792-5. doi: 10.1023/a:1011981317451. PMID 9834005.

Genty M, Gonzalez G, Clere C, Desangle Gouty V, Legendre JY. Determination of the passive absorption through the rat intestine using chromatographic indices and molar volume. Eur J Pharm Sci. 2001 Jan;12(3):223-9. doi: 10.1016/s0928-0987(00)00175-5, PMID 11113641.

Shah I, Vyas J. Role of P-gp inhibitors on gut permeation of metformin: an ex-vivo study. Int J Pharm Pharm Sci. 2022 Oct 1;14(10):18-23. doi: 10.22159/ijpps.2022v14i10.45135.

Kaul S, Ritschel WA. Studies of the intestinal transfer of coumarin and 7-hydroxycoumarin across guinea pig and rat small intestine. Arzneimittelforschung. 1981;31(5):790-5. PMID 7196737.

Meijerman I, Beijnen JH, Schellens JH. Herb-drug interactions in oncology: focus on mechanisms of induction. Oncologist. 2006 Jul-Aug;11(7):742-52. doi: 10.1634/theoncologist.11-7-742, PMID 16880233.